Crestchem FY26 results: 15 percent dividend, new Oleo Biosciences subsidiary

Related Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹143.95

prior close

₹148.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-2.9% vs market

Specialty Chemicals peers, median of 94sector+0.3%-2.4% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-1.4

15m

-1.4

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.8-2.9+0.3-2.4

Next day

+0.0+0.1-0.1-0.4+0.5

-4.8+0.0-4.9+0.2-5.0

-9.4-0.6-8.8-0.7-8.7

-9.0-0.9-8.1-0.8-8.2

-9.3+0.2-9.5-0.6-8.7

-10.4+1.2-11.5+0.3-10.6

15d

-12.5+0.7-13.2+0.0-12.5

-9.5-0.4-9.0+0.4-9.9

-13.5+5.2-18.7+4.1-17.6

+9.1+5.4+3.7+4.0+5.1

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Crestchem board approved audited FY26 results and recommended Rs 1.50 per share final dividend (15 percent) for shareholder approval. Profit for the year rose to Rs 375.74 lakh from Rs 365.68 lakh. Total assets grew to Rs 1,628.92 lakh from Rs 1,054.48 lakh. New subsidiary Oleo Biosciences (75 percent holding) was formed in Bangalore, with up to Rs 2.25 crore investment approved. Auditor gave a clean (unqualified) opinion on both standalone and consolidated results.

Likely market impact

Positive signals: dividend payout, strong asset growth, and clean audit. New subsidiary is not yet operational, so near term impact on earnings is limited.